Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
What happens when you test a psychedelic compound in one of the largest and most rigorous depression trials ever conducted? The answer, published in the New England Journal of Medicine in 2022, is both promising and nuanced. The COMPASS Pathways Phase 2b trial of psilocybin for treatment-resistant depression generated headlines — and legitimate scientific debate — about whether psychedelic-assisted therapy could become a mainstream psychiatric treatment. The findings deserve careful examination beyond the headlines.
Goodwin GM and colleagues conducted a randomized, double-blind, phase 2b trial involving 233 participants across 22 sites in 10 countries. All participants had treatment-resistant depression, defined as failure to respond to at least two adequate courses of antidepressant medication. Participants were randomly assigned to receive a single dose of psilocybin at one of three levels — 25 mg, 10 mg, or 1 mg (the 1 mg serving as an active control) — administered alongside psychological support from trained therapists.
The primary endpoint was change in Montgomery-Asberg Depression Rating Scale (MADRS) score at three weeks. The 25 mg group showed a statistically significant reduction in MADRS scores compared to the 1 mg control group, with a between-group difference of -6.6 points. At three weeks, 29 percent of the 25 mg group were in remission (MADRS score of 10 or less), compared to 8 percent in the 1 mg group. The 10 mg group did not show a statistically significant difference from the 1 mg control, suggesting a dose-response relationship.
However, the picture was not uniformly positive. By 12 weeks, the treatment effect had diminished, and the difference between groups was no longer statistically significant. Adverse events were common, including headache, nausea, dizziness, and fatigue. More concerning, suicidal ideation was reported in some participants across all groups, and there were instances of self-harm and suicidal behavior, though these occurred in a population already at elevated risk. The investigators noted that the study was not powered to draw definitive conclusions about safety in this regard.
The COMPASS trial represents a significant milestone: it is the largest controlled psilocybin trial for depression to date and was published in one of the world's premier medical journals. The demonstrated efficacy of the 25 mg dose at three weeks is clinically meaningful, particularly in a treatment-resistant population where any response is hard-won. The 29 percent remission rate, while modest in absolute terms, is notable given that these patients had already failed multiple conventional treatments.
The waning of effects by 12 weeks raises important questions about durability and whether repeated dosing or integration protocols might sustain improvement. This parallels a similar conversation in ketamine research — rapid-acting treatments may require thoughtful maintenance strategies rather than one-time administration. It is worth noting that psilocybin remains a Schedule I controlled substance in the United States and is not FDA-approved for any indication. The Phase 3 trial program is ongoing.
For clinicians following the psychedelic medicine field, this trial underscores both the potential and the challenges ahead. The therapeutic model — which requires trained therapists, preparation sessions, an eight-hour dosing day with one-to-one supervision, and integration sessions — is resource-intensive and fundamentally different from prescribing a daily medication.
If you are interested in psilocybin therapy for depression, it is important to understand the current landscape. Psilocybin is not yet available as a legal prescription treatment in most of the United States. Clinical trials remain the primary access point. The COMPASS results are encouraging but preliminary, and more data is needed before psilocybin could receive FDA approval.
In the meantime, ketamine remains the most accessible rapid-acting treatment for depression, available as an off-label prescription under physician supervision. For patients with treatment-resistant depression who are drawn to the concept of rapid-acting, neuroplasticity-promoting treatments, ketamine therapy can be initiated now while the psilocybin evidence base continues to develop.
The COMPASS Pathways trial demonstrated that a single 25 mg dose of psilocybin with psychological support significantly reduced depression symptoms at three weeks in treatment-resistant patients, though effects diminished by 12 weeks. The findings support psilocybin's therapeutic potential while highlighting the need for further research on durability, safety, and the optimal treatment model.
Reference: Goodwin GM, et al. "Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression." New England Journal of Medicine. 2022;387(18):1637-1648. DOI: 10.1056/NEJMoa2206443.
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
